Our Top Five Biotech Acquisition Candidates
M&A activity grew in 2010, and we expect deal volume to remain strong in 2011.
Karen Andersen: I am Karen Andersen, senior biotechnology analyst at Morningstar.
With me today to discuss the biotech M&A takeout environment is Lauren Migliore, also a biotech analyst here at Morningstar.
Karen Andersen does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.